Pheochromocytomas (PCCs) and paragangliomas (PGLs) are described in several species. In humans and dogs they have many similarities: the excessive catecholamine release in hormonally active PCC causes similar clinical signs, the frequency of metastasis is similar, and they are histopathologically almost identical. Surgery is curative when PCC and PGL have not metastasized, while only palliative treatment is possible for patients with metastatic disease. Mutations in succinate dehydrogenase subunit B (SDHB) are associated with metastatic behaviour in human PCC/PGL and the same mutation has been described in dogs. The dog might therefore be a suitable model for study of the pathogenesis of metastatic PCC and PGL in humans. Further molecular studies of common tumourigenic pathways and comparative studies of histopathology of human and canine PCC and PGL are warranted.
Introduction
Pheochromocytomas (PCCs) are tumours arising from the chromaffin cells in the adrenal medulla. Paragangliomas (PGLs), also called chemodectomas, are extra-adrenal tumours that arise from sympathetic paraganglia (sPGL) and parasympathetic paraganglia (pPGL). 1 PCC are characterized by overproduction of catecholamines such as epinephrine and norepinephrine. 2 In humans, PGL arising in the thorax, abdomen and pelvic regions (together called sPGL) are also characterized by overproduction of these hormones, particularly norepinephrine, while PGL from the head and neck region (pPGL) are generally biochemically silent. 2 In contrast, the endocrine activity of PGL in dogs has not yet been demonstrated. 3 -7 In humans, PGL are only considered to be malignant if a distant metastasis has occurred; locally invasive behaviour is not predictive of metastatic behaviour. 8 Due to a lack of prognostic biomarkers, it is still not possible to predict aggressive behaviour of PCC and PGL. In general, the frequency of metastatic behaviour is around 10%, but it is around 30% in human patients who carry the succinate dehydrogenase subunit B (SDHB) mutation, and those with sPGL. 9 As driver mutations have been found in more than 22 genes of human PCC and PGL, they are tumours with very high genetic heterogeneity. 10, 11 Around two-thirds of all PCC and PGL are caused by germline and somatic mutations in one of the known susceptibility genes. Although understanding of the pathogenesis of PCC and PGL in humans has increased, little is known about the genes and pathways that drive metastatic behaviour. Some patients with metastasized PCC/PGL make a full or partial response to chemotherapy, but in general few patients benefit from the treatment. Consequently, human patients have a relatively poor 5-year survival approximately 60%, once metastasis has occurred. 12 SDHB has been associated with metastatic behaviour of PCC and PGL in human patients, but until recently there were no available animal model with germline or somatic mutations in one of the SDH genes present in PCC/PGL. However, Holt et al. reported germline and somatic mutations in a small series of dogs with PCC/PGL, which indicates that there is a common tumourigenic pathway in human and canine PCC/PGL. Also, dogs appear to be a much more appropriate than mice for the study of human disease, because tumours in dogs more closely resemble those in humans with respect to biology, size, histology and the efficacy and toxicity of chemotherapies. 13 The aim of this review is to assess the comparative aspects of canine and human PCC and PGL in order to determine whether dogs are an appropriate animal model for the study of PCC and PGL in humans.
Epidemiology and pathology
The combined prevalence of human PCC and PGL varies between 0.2 and 0.6% in autopsy series. 9 The median age at diagnosis of PCC is 24.9 year for patients with hereditary disease and 43.9 year for non-syndromic disease. 14 In humans, PGL occur in the head and neck region, mediastinum, thorax and abdomen. 15 Usually, PCC and PGL are large tumours with an average diameter of 7.2 cm (3-13 cm) and 4.5 cm (2.2-10.5 cm), respectively. 16, 17 In approximately 10% of human patients with PCC the tumours are bilateral, although in patients with hereditary syndromes such as multiple endocrine neoplasia type 2, the prevalence of bilateral PCC is 50-80%. 18 PCC and PGL account for approximately 0.01-0.1% 19 and 0.2%, 20 respectively, of all canine tumours. These are probably underestimates, because they are mainly based on autopsy findings. Biochemical diagnosis of PCC in dogs has only become possible in recent years. 21, 22 In dogs, PGL are most frequently found at the base of the heart (aortic PGL), 23 -25 but posterior mediastinal and extra-adrenal retroperitoneal PGL have also been reported. 6, 26, 27 The age at diagnosis ranges from 1.6 to 18 years for PCC 28, 29 and from 1.5 to 12 years for PGL. 7,28 -32 Canine PCC and PGL do not appear to be breed related, however, a link between the increased incidence of chemoreceptor neoplasia and chronic hypoxia was proposed in brachycephalic breeds. 33 Canine PCC are relatively large tumours, with an average diameter of 5. 
Clinical presentation
PCC has been called the great mimic, as similar clinical signs and symptoms are produced by many other, more common clinical conditions. The clinician's awareness of PCC in humans represents a crucial initial step in the diagnosis, but confirmation requires biochemical evidence of excessive catecholamine production and diagnostic imaging. 57 Clinical signs of a PCC are usually related to the direct actions of secreted catecholamines and/or the space-occupying or invasive nature of the adrenal mass. Hormone secretion from the tumour is episodic and unpredictable, and measured circulating levels of catecholamines in humans are related to the position (sitting or supine) of the patient at the time of blood sampling. 58 The episodes of high catecholamine release may occur several times per day or only at intervals of weeks to months. Their severity varies from mild to life-threatening and may progress with time. 52, 59 In dogs, the clinical manifestations of catecholamine excess are often non-specific, such as weakness, abdominal pain and discomfort. Those related to the cardiorespiratory system include panting, tachycardia, arrhythmias and collapse. 28, 29 Among arrhythmias, premature supraventricular and ventricular complexes and tachycardia are the most common. Rarely, a PCC can also be associated with bradycardia and an atrioventricular (AV) block. 39, 60 The conduction disturbances are due to myocardial damage, ischaemia and fibrosis, which are a result of prolonged exposure to catecholamines from the PCC. Myocardial lesions in dogs with PCC similar to those in humans with PCC-associated cardiomyopathy have also been described. 61 Arterial hypertension, one of the hallmarks of PCC, is present in about 50% of affected dogs at the time of examination. Consequently, a failure to document systemic hypertension obviously does not rule out the disease. 22, 28 The neuromuscular system in dogs with PCC may be affected by catecholamine-induced vasospasm, bleeding in the CNS or metastasis. 29 Paresis, lameness and pain have been reported as a result of metastases to the vertebral canal or bone. 34, 62, 63 The invasive nature of PCC commonly leads to occlusion of the caudal vena cava. 41 In addition, large PCC are predisposed to necrosis and bleeding and can lead to hemoabdomen. 64 The most common clinical signs and findings in dogs with PCC are presented in Table 1 .
Canine PGL usually present with spaceoccupying effects, local invasion and metastasis, and interference with the function of adjacent organs and vital structures. Carotid body PGLs can hamper swallowing and may cause dyspnea or circulatory disturbances due to compression. 5 PGL are typically large at presentation and often invade into the adjacent structures including the base of the skull, tympanic bulla and cranial cavity, causing neurologic deficits associated with the nerves in that area, such as Horner's syndrome, dysphonia, dysphagia and facial paralysis. 65 Spinal invasion or metastatic spread of a mediastinal PGL can cause paresis and paralysis. 7,66,67
Diagnosis

Biochemical testing
Biochemical evaluation of PCC includes measurement of plasma or urinary catecholamines and their metabolites, metanephrine (MN) and normetanephrine (NMN), the so-called metanephrines. 68 The principle of measuring metanephrines is based on the intramedullary metabolism of catecholamines. The production and secretion of metanephrines in tumour cells is continuous and more accurately reflects tumour mass than the release of catecholamines, which is usually episodic. 69 In humans, measurement of urinary fractionated metanephrines or plasma free metanephrines provide better diagnostic sensitivity than urinary or plasma measurements of catecholamines and catecholamine metabolites. 1, 68 In dogs, biochemical testing for PCC has only recently been initiated and involves analysis of urine or plasma. Measurement of urinary catecholamines is performed in a single voided sample and their concentrations are expressed as ratios to the creatinine concentration in the same urine sample. 22, 53, 70 The NMN-to-creatinine ratio has a higher sensitivity than the MN-, epinephrine-and norepinephrine-to-creatinine ratios in the diagnosis of canine PCC. 70 Corresponding to urinary measurements of NMN, measurement of plasma free NMN is superior to measurement of plasma free MN. 53, 71 Currently, there is no consensus about the use of plasma or urine, but there is a strong preference for NMN determination. 53 Plasma free NMN and MN are much higher in healthy dogs than in healthy humans, so for the interpretation of the results, the availability of species-specific reference ranges is essential. Another important aspect in the interpretation of the results of biochemical testing in dogs is the discrimination between a PCC and hypercortisolism due to a cortisol-secreting adrenocortical tumour ( Table 2 ). The similarities in clinical features of a PCC and hypercortisolism make the differentiation quite challenging. In addition, endogenous and exogenous glucocorticoids have physiological interactions with catecholamines and increase their production. 69 Studies of the biochemical evaluation of PCC have included groups of dogs with hypercortisolism and the best discriminatory parameter appears to be NMN, in either urine or plasma. 57 -59 Alternatively, measurement of serum inhibin can be helpful in dogs. Inhibin levels should be undetectable in dogs with PCC, but not in those with hypercortisolism. 72 This measurement is not applicable in sexually intact dogs because gonadal and adrenocortical inhibin cannot be distinguished in serum.
Diagnostic imaging
Several imaging techniques have proved useful for visualization of PCC/PGL and for assessing their shape, architecture, size, margination of the mass, invasion of adjacent structures and, in case of PCC, the symmetry of the adrenal glands. 9, 52 In humans, imaging studies are recommended to locate PCC/PGL only after clear biochemical evidence. Computerized tomography (CT) has been preferred over magnetic resonance imaging (MRI), because of its excellent spatial resolution of the thorax, abdomen and pelvis.
9 MRI is recommended in patients with metastatic disease or an allergy to CT contrast media and in whom radiation exposure should be limited. In dogs, PCC/PGL are most often evaluated by ultrasonography (Fig. 1A) , mainly because this technique is generally available and requires no anaesthesia. 73 Not unusually, PCC is diagnosed after an incidental adrenal mass is visualized during abdominal ultrasonography for an unrelated problem. 74 There is no sonographic appearance that is typical for canine PCC. Most are unilateral and the contralateral adrenal gland is of normal size and shape, but about 10% are bilateral . 51, 73 Cortisol-secreting adrenocortical tumours remain the most challenging differential diagnosis. 75 Both tumour types can be bilateral and even if a unilateral lesion is present, the atrophy of the contralateral adrenal gland is difficult to establish or may even not be apparent. 76 Features that need to be evaluated during ultrasonography are possible invasion of surrounding structures and the presence of metastasis. The resulting tumour thrombi consist of non-vascular tumour extending into the vessel. It is likely that these thrombi invade the phrenicoabdominal vein first and then extend into the caudal vena cava. In various studies an invasion of up to 50% is ascribed to PCC. 38, 50, 51, 77 It remains disputable, whether this relatively high percentage might be even higher, because only dogs in which surgery was a realistic therapeutic option, were included in cited studies. Another explanation could be that this is a result of relative late diagnosis of a PCC, because biochemical diagnosis was not generally available so far and clinical signs are quite common and not entirely exclusive for PCC. In humans, invasive growth is not synonymous with malignancy as it may only represent expansion of a large tumour mass into structures with minimal resistance. This has been suggested for canine PCC as well, but there is as yet no consensus about the definition of malignancy. The correlation between tumour size and invasiveness will need to be addressed in the future. CT allows precise determination of the size, shape and architecture of the PCC/PGL and is superior to ultrasound for detecting vascular invasion (Fig. 1B) . 78 No complications related to the contrast medium have been reported in dogs with PCC/PGL. 73 Currently, CT scanning is the gold standard in dogs with PCC/PGL and an absolute prerequisite when surgical intervention is planned. 50 The additional benefit of CT scanning is that abdominal imaging can be combined with thoracic screening for the presence of metastasis. There have as yet been no reports of MRI imaging of PCCs in dogs but there has been one report of imaging of a carotid PGL. 5 In human patients with metastatic PCC/PGL, 123 I-metaiodobenzylguanidine (MIBG) scintigraphy has been advocated for functional imaging. 9 There is little experience with functional imaging of PCC in veterinary medicine: two case reports exist of dogs with PCC diagnosed by 123 I-MIBG scintigraphy 79 and one position emission tomography (PET) with 18 F-MIBG (fluorobenzylguanadine). 80 
Histopathology and immunohistochemistry
The cells of the adrenal medulla and the paraganglia of the autonomic nervous system are derived from the neural crest during embryogenesis. 81 The adrenal medulla and paraganglia mainly consist of two types of cells: type 1 or chief cells, produce catecholamines and type 2 or sustentacular cells, provide structural support. Histologically, PCC and PGL are almost identical. They are characterized by polygonal basophilic neoplastic cells with rounded nuclei, arranged in nests, surrounded by a fibrovascular stromal network (Fig. 2) .
No histological features of PCC/PGL predict metastatic behaviour. Although certain histological features in other tumour types are predictive of metastatic behaviour, such as invasion of blood vessels or the surrounding tissue, these are not proof of malignancy in patients with PCC/PGL. Furthermore, PCC and PGL without any signs of invasive behaviour may present with metastases. 82 Two scoring models have been proposed to evaluate the predictive behaviour of human PCC and PGL. Haematoxylin and eosin (H&E), SYP and NSE stainings of a normal canine adrenal and a canine pheochromocytoma. SYP produces specific staining of the adrenal medulla and is positive in the pheochromocytoma. NSE also stains the pheochromocytoma, but is not specific for the adrenal medulla, as the zona glomerulosa (most outer layer of the adrenal cortex) also stains strongly. [Colour figure can be viewed at wileyonlinelibrary.com] They are the 'Pheochromocytoma of the Adrenal gland Scaled Score' (PASS) 83 and the 'Grading system of Adrenal Pheochromocytoma and Paraganglioma' (GAPP). 84 Unfortunately, an independent study revealed a high degree of inter-observer variation in the PASS scoring and demonstrated that this system is too sensitive for individual scoring and cannot be used for predicting malignant behaviour. 85 In addition, although it appears to be a promising scoring system for the identification of PCC and PGL with metastatic potential, the GAPP scoring has not yet been validated by an independent multi-observer study.
A three-tier grading system has been proposed for use in dogs to distinguish among (1) benign PGL (grade I -low mitotic rate, no invasion or metastasis), (2) mildly aggressive (grade II -low mitotic rate, less uniform cells, locally invasive tumours or metastasis) and (3) aggressive PGL (grade III -high mitotic rate, cellular pleomorphism, locally invasive growth or metastasis). 23 This grading system has not been applied in routine 9/9 9/9 9/9 -PGL Phan et al. 42 1/1 ---PGL Wey and Moore 31 1/1 ---PGL Yamamoto et al. 32 12/13 -13/13 0/13 PGL Yanagawa et al. 49 1
diagnosis and has not been validated by a second study. For canine PCC, a TNM classification has been applied in two large-scale studies. High frequencies of 39 and 52% for local invasive behaviour have been reported, of which 13 and 24%, respectively, presented with distant metastases. 28, 29 Hence, it appears that in dogs, invasive growth can be an indication of malignant behaviour, but is not always predictive for the presence of metastases at diagnosis or during follow-up, in accordance with the histopathological findings in human PCC. In humans and dogs, diagnosis of PCC and PGL is supported by immunohistochemistry using several markers, including chromogranin A (CrA), synaptophysin (SYP) and neuron-specific enolase (NSE) which stain the chromaffin cells, and S100, which is specific for the sustentacular cells. 7,23,26,40 -42,44,46-49,86-88 The markers have high sensitivity for diagnosing PCC, but not for diagnosing PGL (Table 3 ). This could be due to the grade of the PGL, as Aresu et al. reported that loss of CrA and S100 expression occurred in all of the most aggressive PGLs (grade III) 23 , that had invasive or metastatic behaviour and a high mitotic rate (greater than four per field), while NSE-positive staining remained in all studied tumours. 86 However, another study showed there were grade III tumours with positive staining for CrA (two of seven) and SYP (four of seven), while losing NSE staining in two of seven grade III PGL. 23 Furthermore, in addition to staining the adrenal medulla, NSE also stains the zona glomerulosa (Fig. 2) , so this marker is not specific for PCC. SYP and CrA seem to be the most specific markers for diagnosing PCC, but biochemical testing for catecholamines will provide additional proof to confirm the diagnosis.
Treatment
Adrenalectomy is the preferred treatment for PCC, because removal of the PCC will reverse the clinical signs and symptoms associated with excessive catecholamine release and avoid the complications of uncontrolled growth of the tumour. 89 Complications occurring during surgery are mainly catecholamine-induced effects, which may be serious and potentially life-threatening. Prerequisites for a successful outcome are preoperative medical treatment, an experienced anaesthesiologist, a skilled surgeon and intensive post-operative care. 57 Catecholamine-induced complications associated with surgical removal of PCC in dogs include hypertensive crisis, cardiac arrhythmias, pulmonary oedema and cardiac ischaemia. 28 In order to avoid them, treatment with phenoxybenzamine should be initiated at least 2 weeks prior to adrenalectomy. 77 Phenoxybenzamine is an -adrenergic receptor antagonist that irreversibly binds to -1 and -2 adrenergic receptors and blocks the -adrenergic response to circulating epinephrine and norepinephrine. 89 The mortality rate after adrenalectomy was significantly lower in dogs pretreated with phenoxybenzamine than in untreated dogs. Furthermore, this pretreatment also prevents post-operative hypotension and hypovolemia. 88 Laparoscopic adrenalectomy has gained in popularity in veterinary medicine and observational studies have shown that it results in more rapid recovery, shorter hospitalization, fewer wound complications and shorter surgical time than open laparotomy. 90, 91, 92 The size of the PCC and the extent of vascular invasion are the most important criteria in choosing between laparoscopy and open laparotomy. Masses up to 5 cm in diameter without invasion of the caudal vena cava are amenable to laparoscopy, while open adrenalectomy is indicated if there is vascular invasion. 38, 93, 94 Significant prognostic indicators for survival of dogs with PCC after adrenalectomy include lack of intraoperative arrhythmias, pretreatment with phenoxybenzamine, younger age and short duration of surgery. 77 There was no association between size of the tumour or presence of vascular invasion and survival, but it is possible that the presence of vascular invasion increased surgical time and thus indirectly influenced survival. In line with this, extended invasion of the caudal vena cava beyond the hepatic hilus was associated with a higher post-operative mortality rate, but did not affect long-term prognosis. 50 The only possible treatment of PGL in dogs is surgery and its success greatly depends on the localization of the tumour. 7, 24, 30, 31, 45, 49 If the tumour is inoperable or surgery is prevented by concurrent disorders or for other reasons, medical treatment with phenoxybenzamine is indicated. It will not affect the secretion or growth of the PCC, but blocks the -adrenergic response to circulating catecholamines. 77 Treatment with metaiodobenzylguanidine labelled with radioactive iodine ([ 131 I] MIBG) has been reported to result in partial remissions of PCC in humans. 95 In dogs, this treatment has only been applied once and has led to a clinically stable disease for 4 months. 79 There are as yet insufficient data for an appraisal of the survival of dogs with PCC receiving medical treatment alone or [ 131 I] MIBG .
Comparative genetics
In addition to the histological and immunohistochemical similarities of PCC/PGL between humans and dogs, it appears the tumours share common disease pathways. In humans, as previously indicated, PCC and PGL have been associated with germline and somatic mutations in at least 22 genes. 11 The most frequently mutated genes include RET, VHL, NF1, SDHB and SDHD, all of which are associated with syndromes when there is a germline mutation. 11 SDHB and SDHD encode two of the four subunits of mitochondrial complex II. Human patients with germline mutations in one of the mitochondrial complex II genes have the PCC-PGL syndrome, which is characterized by the manifestation of both PCC and PGL, and in rare cases gastrointestinal stromal tumours and clear cell renal cell carcinomas. 96 The penetrance and malignant behaviour of the tumours varies among the different genotypes, but the highest frequency of metastatic tumours is seen in SDHB carriers (∼30%). 96 Eight canine patients with multiple PCC and/or PGL have been described in a small number of reports, suggesting the presence of a germline mutation. 22, 26, 36, 42, 47, 53 However, these studies did not include genetic screening of the canine tumours, so the presence of germline mutations in these cases remains unknown.
Only one study has investigated canine PCC and PGL for the germline and somatic mutations that occur in human PCC/PGL-associated genes; Holt et al. investigated SDHB and SDHD for gene mutations in a series of eight cases (six PCC and two carotid PGL) and found mutations in 50% of them. 97 The mutations included one SDHB (p.Arg38Gln; germline) and three SDHD mutations (p.Lys122Arg; two germline and one somatic). Although the SDHB-Arg38Gln and SDHD-Lys122Arg mutations have never been described in human PCC or PGL (Leiden Open Variation Database), the amino acids are highly conserved among various species, from humans to zebrafish, which implies that the mutations pathogenic. 97 Furthermore, both variants are predicted as pathogenic using the Alamut software (http://www.interactive-biosoftware.com/alamutvisual/). Future genomic and genetic studies should provide more clues about the involvement of common genes and pathways in PCC and PGL in both species.
Conclusions
PCC and PGL are rare tumours in both humans and dogs. In dogs, PCC are clinically different from PGL, as only PCC are known to overproduce catecholamines, whereas PGL are biochemically silent. In humans, PGL occurring in the head and neck region are also biochemically silent, but in contrast to canine PGL, human PGL in the thorax and abdomen are well known for their overproduction of catecholamines. In case of a biochemically active tumour, humans and dogs appear to exhibit the same clinical signs induced by the excessive amounts of catecholamine released by the tumour. In general, the frequency of metastatic behaviour for canine PCC/PGL appears to be in the same range as human PCC/PGL, although if tumour location is taken into account, human PGL of the thorax and abdomen tend to have a higher frequency of metastases. PCC and PGL are histopathologically almost identical. This similarity is also emphasized by the presence of SDHB and SDHD mutations in PCC and PGL in both species, indicating common pathways in the tumourigenesis of human and canine PCC and PGL.
In conclusion, this review shows that the dog might be a suitable model for the study of human PCC and PGL and emphasizes that the comparative pathology of PCC/PGL could provide new insights into the pathogenesis of human metastatic PCC and PGL.
